- Home
- CI vs BMY Comparison
CI vs BMY Comparison
Compare CI & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CI
- BMY
- Stock Information
- Founded
- CI 1792
- BMY 1887
- Country
- CI United States
- BMY United States
- Employees
- CI N/A
- BMY N/A
- Industry
- CI Medical Specialities
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- CI Health Care
- BMY Health Care
- Exchange
- CI Nasdaq
- BMY Nasdaq
- Market Cap
- CI 88.3B
- BMY 97.6B
- IPO Year
- CI N/A
- BMY N/A
- Fundamental
- Price
- CI $295.69
- BMY $47.38
- Analyst Decision
- CI Strong Buy
- BMY Hold
- Analyst Count
- CI 17
- BMY 16
- Target Price
- CI $386.76
- BMY $58.00
- AVG Volume (30 Days)
- CI 1.9M
- BMY 14.5M
- Earning Date
- CI 07-31-2025
- BMY 07-31-2025
- Dividend Yield
- CI 2.04%
- BMY 5.24%
- EPS Growth
- CI 46.10
- BMY N/A
- EPS
- CI 17.99
- BMY 2.67
- Revenue
- CI $255,368,000,000.00
- BMY $47,636,000,000.00
- Revenue This Year
- CI $7.17
- BMY N/A
- Revenue Next Year
- CI $4.15
- BMY N/A
- P/E Ratio
- CI $16.43
- BMY $17.74
- Revenue Growth
- CI 23.96
- BMY 4.62
- 52 Week Low
- CI $262.03
- BMY $41.61
- 52 Week High
- CI $370.83
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- CI 32.54
- BMY 49.27
- Support Level
- CI $299.54
- BMY $46.18
- Resistance Level
- CI $306.46
- BMY $48.36
- Average True Range (ATR)
- CI 6.42
- BMY 1.08
- MACD
- CI -2.22
- BMY 0.10
- Stochastic Oscillator
- CI 5.30
- BMY 49.39
About CI The Cigna Group
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.